Non-alcoholic and alcoholic fatty liver disease in patients suffering from biliary tract pathology and obesity: clinical and functional aspects by Filippova, A.
Modem Science •— Modem! veda 2015 № 4
NON-ALCOHOLIC AND ALCOHOLIC FATTY LIVER DISEASE 
IN PATIENTS SUFFERING FROM BILIARY TRACT 
PATHOLOGY AND OBESITY: CLINICAL AND FUNCTIONAL
ASPECTS
Aleksandr a Filippova, 
candidate o f Medical Sciences, 
associate professor of Hospital Therapy No. 1 and 
Occupational Diseases Department,
State Institution «Dnepropetrovsk Medical Academy 
of the Ministry o f Health o f Ukraine»
Annotation. Fatty liver disease o f different genesis is very often accompanied by biliary 
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with accompanying biliary tract and obesity pathology include intensity o f clinical 
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moderate manifestations o f cytolysis and mesenchymal in f animation.
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Introduction. Liver involvement due to pathology of hepatobiliary system (HBS) of 
non-alcoholic and alcoholic etiology is characterized by combination of different etiologi­
cal and pathogenic mechanisms and belongs to the group of conditions, incorporated under 
the title “fatty liver disease” (FLD). Formation of FLD of different etiology in patients 
suffering from biliary tract pathology (BT) and obesity takes place against the background 
of poor metabolic compensation, activation of lipid peroxygenation processes and reduc­
tion in antioxidant protection activity, endogenous intoxication, obesity, insulin resistance 
or type 2 diabetes mellitus with significant daily fluctuations of glycemia, increase of bili­
ary acids contents in blood serum and characteristic parameters of cytolysis [2, 12, 15].
Currently a non-alcoholic fatty liver disease (NAFLD), prevalence of which is rapidly 
growing in both economically and socially developed countries, as well as in developing 
countries [9, 10], is one of the most serious problems of internal medicine in general. 
Prevalence of NAFLD amounts to 10^10% in the general population, 30-100%— among 
those suffering from obesity, 20-92 % — among dyslipidemia patients, 10-75 % — 
among those suffering from type 2 diabetes mellitus [9]. About 30% of patients diagnosed 
with steatosis develop non-alcoholic steatohepatitis, which in 10% of cases can be subse­
quently transformed into hepatic cirrhosis [13]. Unfortunately, prevalence of NAFLD in 
Ukraine is under-investigated. Chronic liver involvements of alcoholic genesis retain their 
role in the structure of general liver pathology, being currently characterized as alcoholic 
fatty liver disease (AFLD). Alcohol abuse is an important medical and social problem 
worldwide, especially in the US, Europe, including in Ukraine. According to statistical 
data, 4,65 % of Americans meet the criteria for alcohol abuse, while 3,81 % — meet the 
criteria for alcohol dependence [1, 14]. Daily consumption of alcohol in a dose of more 
than 60 grams per day leads to development of alcoholic hepatic steatosis (AHS), which in
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5-15% of cases progresses to fibrosis and hepatic cirrhosis [6]. 10-35 % of patients, which 
hospitalized with alcohol abuse, are diagnosed with alcoholic steatohepatitis (ASH) [1, 
14]. There are no reliable data on AFLD prevalence in Ukraine.
It was established, that FLD is often associated with inflammatory processes in bile 
ducts and gallbladder in the form of chronic non-calculous or calculous cholecystitis, as 
well as with pathological conditions after carrying out of cholecystectomy and obesity [2, 
7, 15]. In these instances it is possible to speak of concurrent (comorbid) or conjugated 
pathology within HBS of non-alcoholic and alcoholic genesis and obesity. Biliary dyskine­
sia and chronic inflammatory processes of BT are often developed against the background 
of steatoses and steatohepatitis, thus adding to more severe violations in functions and 
structure of the liver, which in its turn fosters torpid course of the disease and complica­
tions [8].
Clinical manifestations of FLD are minimal. The majority of patients (48-100%) lack 
symptoms, characteristic, of liver disease. There are no specific markers of FLD diagnos­
tics [10, 12]. Quite often FLD is diagnosed after the hepatomegalia or unexplained in­
crease in transaminases has been revealed [12]. Thus, the disease is asymptomatic in most 
patients, though comorbid course of the disease may be characterized by active clinic man­
ifestation and more complicated course.
Irrespective of the rapid spread of HBS pathology within the population some clinical 
and functional aspects of FLD of non-alcoholic and alcoholic genesis against the back­
ground of biliary tract pathology and obesity, despite the availability of published data, 
remain not fully investigated. Therefore, the problem of timely diagnostics of FLD in pa­
tients, which are suffering from biliary tract pathology and obesity, remains relevant today.
Objective. To explore the clinical and laboratory manifestations of FLD of 
non-alcoholic and alcoholic genesis in patients, which are suffering from biliary tract pa­
thology and obesity.
Materials and Methods. 300 patients diagnosed with FLD of non-alcoholic and al­
coholic genesis with obesity and accompanying biliary tract pathology: chronic 
non-calculous cholecystitis (CNCC), chronic calculous cholecystitis (CCC), patients with 
condition after laparoscopic cholecystectomy and patients with postcholecystectomy syn­
drome (PCS), in which revealed signs of FLD during sonographic examination or morpho­
logical examination of liver biopsy. The age composition of those examined ranged from 
24 to 73 years. Predominantly those were the patients of the employable age within the 
range of 35-59 years. The average age of the patients amounted to 42,1 ±2,02 years. Sex 
composition: 147 (49%) men and 153 (51%) women. Duration of the disease ranged from 
1 to 30 years. The control group consisted of 20 apparently healthy subjects.
The diagnosis of FLD and CNCC, chronic calculous cholecystitis, postcholecystecto­
my syndrome was set in compliance with standardized protocols of diagnosis and treat­
ment of digestive diseases according to the Resolution of the Ministry of Health of 
Ukraine No. 271 as of June 13, 2005 p, ICD-10 and WHO criteria [4], based on the medi­
cal background data, clinical and instrumental (ultrasound examination of the abdominal 
cavity) examination, with due consideration of the data of conventional biochemical pa­
rameters [5]. In order to confirm the alcoholic etiology of FLD the CAGE diagnostic test 
was also applied to [6]. The diagnosis is established by increasing obesity body mass index
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over 30 kg/m2 [11]. All the patients have signed the informed consent form to participate 
in the study.
NAFLD was diagnosed on grounds of increase in liver enzymes level, data of the liver 
ultrasonography (increase in echogenicity of the parenchyma, increase in echo-signal at­
tenuation, smoothing of vascular pattern, hepatomegalia), exclusion of the viral infection, 
autoimmune, hereditary liver diseases, influence of hepatotoxic factors [4, 5]. The diagno­
sis of AFLD was based on combination of characteristic features, and namely on assess­
ment of the patient’s complaints, anamnestic data as regards of alcohol abuse (daily con­
sumption of alcohol in a dose of more than 60 grams per day), clinical and laboratory man­
ifestations of liver disease with due consideration of CAGE test parameters [4, 6].
Activity of NASFI and ASH was assessed according to serum glutamic pyruvic trans­
aminase (ALAT) level: the minimum level provided^ increase in serum glutamic pyruvic 
transaminase (ALAT) amounted to 3-fold normal range, moderate one from 3- to 5-fold 
normal range, while the high one to more than 5-fold normal range.
In order to objectivize the subjective and objective manifestations of disease among 
the examined patients we have resorted to assessment of clinical signs using 3-point scale:
0 — absence of clinical syndrome signs;
1 — manifestations of clinical syndrome are minimal and appear not systematically;
2 — manifestations of clinical syndrome are permanent, moderately expressed;
3 — manifestations of clinical syndrome are permanent, expressed, reduce the quality 
of life and working capacity.
The assessment of liver’s functional capacity was carried out using routine methods 
according to levels of protein metabolism (blood levels of total protein, albumins, globu­
lins and their fractions, thymol test), presence of cholestatic syndrome (level of total bili­
rubin, alkaline phosphatase (ALP) and cytolytic (activity of aminotransferase — Serum 
glutamic oxaloacetic transaminase (ASAT) and Serum glutamic pyruvic transaminase 
(ALAT) syndromes [3].
Analysis of the study results was carried out using Statistica software package and 
Excel tables with the use of parametric and nonparametric statistical methods. Quantitative 
indicators provided in the form of the average value and standard error of the mean 
(M±m). The differences were considered significant provided the level of probability 
amounted to p < 0,05.
Results and their discussion. Among 300 of the examined patients, diagnosed with 
FLD and obesity, 200 (66,7%) were diagnosed with NAFLD, 100 (33,3%) had AFLD. The 
patients, diagnosed with NAFLD, were split into 100 (33,3%) patients with the set diagno­
sis of non-alcoholic hepatic steatosis (NAHS-1) and 100 (33,3%) diagnosed with 
non-alcoholic steatohepatitis (NASH-2). The patients, diagnosed with AFLD, were also 
split into 50 (16,7%) patients with the registered alcoholic steatosis of liver (AHS-3) and 
50 (16,7%) more suffering from alcoholic steatohepatitis (ASH- 4).
Among those patients, which suffering from NASH-1, — 70 (70%) were expressing 
minimum activity, 30 (30%) patients were diagnosed with moderate activity of the patho­
logical process. In patients, suffering from ASH, the minimum activity was registered in 
49 (98%) of the patients, moderate — in 1 (2%) patient. FLD of the patients was diag­
nosed against the background of biliary tract pathology and obesity.
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The patients, suffering from NAFLD, were complaining of general weakness, in­
creased fatigability, psychoemotional instability, manifestations of anhedonia (reduction in 
activity and vigor, loss of interest and satisfaction from customary things), headaches, fre­
quent mood changes. Symptoms like these in their totality amounted to asthenic syndrome 
with pronounced autonomic disturbances, diagnosed in 48% of the patients with NAHS-1 
and in 63% of patients suffering from NASH-2 (Table 1), being 1,3 times more frequent if 
to compare to NAHS-1 (p<0,05). The degree of severity of the asthenic syndrome was 
minimum and moderate (Table 2) for the patients with NAHS-1 (0,94±0,11 points on av­
erage), as well as moderate and significant in patients suffering from NASH-2 (1,66±0,14 
points on average) (p<0,05). The development of the asthenic syndrome in patients, suffer­
ing from NAFLD and obesity, may be related to metabolic disorders, phenomena of en­
dogenous intoxication with the emergence of average weight molecules and significant 
disorders of energy metabolism regulation. Prevalence of the main clinical syndromes in 
patients with NAFLD and AFLD accompanied by biliary tract pathology and obesity is 
represented at Figure 1. It was established, that from the clinical prospective the majority 
of patients with NAFLD and obesity complained of constant or periodic nausea or epigas­
tric burning, which arose and got intensified during or after the meals, feeling of bitterness 
or dryness in the mouth, belching, reduction in complete absence of appetite, distended 
abdomen, astrictions or diarrhea, as well as unstable stool with alternating constipation 
with diarrhea. The mentioned symptoms were considered to be manifestations of dyspeptic 
syndrome, which was registered in 77% of patients diagnosed with NAHS-1 and 80% of 
patients diagnosed with NASH-2. Dyspeptic syndrome in patients with NAFLD and obe­
sity may be related to violation of detoxification function of the liver, increase in endoge­
nous intoxication and combined damage to biliary and pancreatic systems accompanied by 
violation in digestive processes.
The data as regards of severity degree of the chief clinical manifestations of disease in 
patients belonging to thematic groups is provided in Table 2. The degree of severity of the 
dyspeptic syndrome was minimum and moderate for the patients with NAHS-1 (averagely 
1,19±0,08) and moderate and significant in patients diagnosed with NASH-2 (1,82±0,11 
on average) (p<0,05).
Nausea after meals was registered with equal frequency in patients suffering from 
NAHS-1 and NASH-2— 23% and 21% respectively. Similar results pertained to the 
symptoms of bitterness in the mouth (29% and 26%), epigastric burning (24% and 28%), 
belching after meals (23% and 24%), which were diagnosed with more or less equal fre­
quency in patients suffering from NAHS-1 and NASH-2 (p>0,05). The average degree of 
severity of nausea after meals was a bit higher in patients diagnosed with NASH-2 and 
amounted to 0,50±0,10 versus 0,29±0,06 in patients suffering from NAHS-1.
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Table /
Prevalence of major clinical and biochemical syndromes in patients 
suffering from non-alcoholic and alcoholic fatty liver disease and obesity
S y n d ro m e s
N A H S -1 ,
n = 1 0 0
N A S H -2 ,
n = 1 0 0
P 1-2 A H S -3 ,
n = 5 0
A S H -4 ,n = 5 0 P34 Pl-3 P2 -4
A b s. % A b s . % A b s . % A b s. %
A s th e n ic 4 8 4 8 63 6 3 < 0 ,0 5 3 9 78 32 6 4 > 0 ,0 5 <0,001 < 0 ,0 5
D y s p e p tic 7 7 7 7 8 0 8 0 > 0 ,0 5 4 7 9 4 4 7 9 4 > 0 ,0 5 <0,01 < 0 ,0 5
A b d o m in a l  p a in 9 8 9 8 9 4 9 4 > 0 ,0 5 5 0 10 0 5 0 1 0 0 > 0 ,0 5 > 0 ,0 5 > 0 ,0 5
H e p a to m e g a l ia 51 51 6 7 6 7 < 0 ,0 5 2 7 5 4 3 4 6 8 > 0 ,0 5 > 0 ,0 5 > 0 ,0 5
C y to ly s is - - 10 0 1 0 0 < 0 ,0 0 1 - - 5 0 1 0 0 < 0 ,0 0 1 > 0 ,0 5 > 0 ,0 5
C h o le s ta t i c 2 4 2 4 45 4 5 < 0 ,0 1 2 6 52 2 9 5 8 /> 0 ,0 5 < 0 ,0 0 1 > 0 ,0 5
M e s e n c h y m a l  in f la m m a ­
to ry
- - 55 5 5 < 0 ,0 0 1 - - 5 0 1 0 0 < 0 ,0 0 1 > 0 ,0 5 < 0 ,0 0 1
L iv e r  c e ll  fa i lu re - - 6 0 6 0 < 0 ,0 0 1 - - 41 82 < 0 ,0 0 1 > 0 ,0 5 < 0 ,0 1
O b e s i ty  I - I I I  g ra d e 6 9 6 9 6 0 6 0 > 0 ,0 5 2 2 4 4 33 6 6 < 0,05 < 0 ,01 > 0 ,0 5
Notes, p i_2_level o f differences significance between the indicators o f NAHS and NASH groups;
P3.4_between AHS and ASH groups; p 1.3 between NAHS and AHS groups; p,.4 between NASH and ASH groups.
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The degree of severity of the main clinical syndromes 
in patients suffering from non-alcoholic and alcoholic fatty liver disease and obesity, abs. (%)
Table 2
S y n d ro m e s, d e g ree  o f  se ­
v e rity
N A H S -1 , n= 100 N A S H -2 , n = 1 0 0 A H S -3 , n= 50 A S H -4 , n= 50
Asthenic
- a b s e n t (0) 52  (52% ) 37  (37% ) 11 (22% ) 1 8 (3 6 % )
- m in im al (1) 1 0 (1 0 % ) 4  (4 % ) 1 6 (3 2 % ) -
-m o d era te  (2) 30  (30% ) 15 (1 5 % ) 21 (42% ) 22 (44% )
-c o n s id e ra b le  (3) 8 (8% ) 4 4  (44% ) 2 (4 % ) 1 0 (2 0 % )
- av e ra g e , M ± m  (M e) 0 ,9 4 ± 0 ,1 1 (0 ) ^ l ,6 6 ± 0 ,1 4 ( 2 ,0 ) T?r 1.2 8 ; 0.12. (1 ,0 ) r 1 ,4 8 ± 0 ,17 (2 ,0 )
Dyspeptic
- a b s e n t (0) 23 (23% ) 20  (2 0 % ) 3 (6% ) 3 (6% )
- m in im a l (1) 38 (38% ) 9 (9 % ) 18 (36% ) -
-m o d era te  (2 ) 36 (36% ) 40  (4 0 % ) 27  (54% ) 34 (68% )
-c o n s id e ra b le  (3) 3 (3% ) 31 (31% ) 2 (4 % ) 13 (2 6 % )
- av e ra g e , M ± m  (M e) iTTôiô^ ôsTbôT7^ H 8 2 ÏÔ X Î (2 ,0 ) ‘-4 2 7 b S Ö jÖ 7 2 jÖ ) U
Abdominal pain
- a b s e n t (0) 2 (2% ) 6 (6% ) - -
- m in im a l (1) 22 (22% ) 1 0 % ) 15 (3 0 % ) -
-m o d era te  (2 ) 60  (60% ) 23 (2 3 % ) 25 (5 0 % ) 29  (58% )
-c o n s id e ra b le  (3) 1 6 (1 6 % ) 70 (7 0 % ) 10 (20% ) 21 (4 2 % )
- av e ra g e , M ± m  (M e) I ,9 0 ± 0 ,0 7  ( 2 ,0 ) 2-3 2 ,5 7 ± 0 ,0 8  (3 ,0 )  M
1,9 0 ± 0 ,10 
( 2 ,0 ) 4
2 ,4 2 ± 0 ,0 7  
( 2 ,0 ) 2'3
Notes. u,3'< __ p<0,05 if compared to an appropriate group.
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The average degree of bitterness in the mouth before meals was more pronounced 
in patients suffering from NAHS-1 and amounted to — 0,09±0,03 if to compare to the 
patients diagnosed with NASH-2 — 0,03±0,03 (p<0,05). However, bitterness in the 
mouth after meals was more frequently diagnosed in patients with NASH-2 — 
0,62±0,11 versus 0,43±0,07 in patients suffering from NAHS-1 (p>0,05). At the very 
same time, complaints of distended abdomen of an average degree of severity 
1,13±0,13 were more characteristic of patients diagnosed with NASH-2 versus 
0,69±0,09 in patients suffering from NAHS-1 (p<0,05).
Patients diagnosed with NAFLD were disturbed by feeling of heaviness, feeling of 
fullness in the right and left subcostal and epigastric areas, pain, which has constant or 
intermittent nature, tender pain, which intensified after meals or physical loads.
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Figure 1. Prevalence of the main clinical syndromes in patients suffering front non-alcoholic 
and alcoholic fatty liver disease accompanied by biliary tract pathology and obesity.
All the mentioned symptoms formed the abdominal pain syndrome, which in case 
of NAFLD and obesity may be related to presence of inflammatory infiltration of liver 
tissue and hepatomegalia. Abdominal pain syndrome was registered in 98% of patients 
diagnosed with NAHS-1 and 94% of patients diagnosed with NASH-2. The degree of 
severity of the abdominal pain syndrome was minimum and moderate for the patients 
with NAHS-1 (1,90±0,07 on average) and moderate and significant in patients suffer­
ing from NASH-2 (2,57±0,08 on average), p<0,05 (Table 2).
In patients of various groups pain in the right and left hypochondrium and epigas­
trium was more frequently related to food intake, with pain without any reason ranking 
second. Pain in the right hypochondrium explained by no reason was more frequently
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registered in patients suffering from NAHS-1 — 21% of cases versus 8% of cases in 
NASH-2 group (p<0,01).
The average degree of severity of the pain syndrome in patients suffering from 
non-alcoholic and alcoholic fatty liver disease and obesity is given in Table 3. The 
highest intensity of pain in the right and left hypochondrium after meals was revealed 
in patients of NASH-2 group — 1,45±0,14 in the right and 0,92±0,13 in the left hypo­
chondrium, what differentiated them from the patients of NAHS-1 group, the average 
pain degree of which amounted to 1,09±0,11 in the right and 0,51±0,09 in the left hy­
pochondrium (p<0,05).
During the abdominal palpation examination of the patients, who were under ob­
servation, the patients of various groups usually revealed moderate tenderness in the 
right, left subcostal and epigastric areas (Figure 2). To be more specific, tenderness on 
palpation in the right hypochondrium was diagnosed in almost all the patients having 
NAFLD— 89% and 81% of cases in NAHS-1 and NASH-2 groups, respectively. 
However, the average degree of the objective severity of pain in the right hypochondri­
um (Table 4) was more intense in patients of NASH-2 group (2,16±0,12) if compared 
to NAHS-1 group (1,71±0,09) provided p<0,05.
Figure 2. Frequency distribution of the pain syndrome revealed within physical examination
depending on the location.
Other objective indicators of tenderness in the upper abdominal area — within the 
area of epigastrium and left hypochondrium — were registered in NAHS-1 and 
NASH-2 groups with equal frequency, though among fewer patients (from 34% to 
47%). As in the previous case, the average degree of pain severity in the left hypo­
chondrium was higher in patients of NASH-2 group (1,10±0,13) if to compare to the 
patients of NAHS-1 group (0,61±0,09) provided p<0,05.
During the physical examination of patients suffering from NAFLD accompanied 
by biliary tract pathology and obesity the hepatomegalia was diagnosed. The patients 
suffering from NASH-2 were more frequently diagnosed with clinical manifestations
pain in the right pain in the left pain in the 
hypochondrium hypochondrium an
epigastric 
rea
g  NAHS-1 0  NASH-2 g  AHS-3 | |  ASH-4
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of hepatomegalia— 67% of cases, versus 51% of cases among patients belonging to 
NAHS-1 group (p<0,05). On palpation of the liver in patients diagnosed with NAFLD, 
having no excessive weight, a sharp or slightly rounded edge of the liver was revealed. 
It was characterized by moderate tenderness and smooth surface, as well as dense or 
tight elastic consistency. Dimensions of the liver determined by percussion according 
to Kurloffs approach in patients suffering from NAHS-1 were higher than standard 
rates (1-st dimension—  12,41±0,2 cm, 2-d dimension— 11,25±0,19 cm, 3-d dimen­
sion— 10,13±0,17 cm). In patients diagnosed with NASH-2 the degree of hepato­
megalia was more pronounced due to increase in activity of the inflammatory process 
and was equal to values as follows: 1-st dimension— 13,86±0,24 cm, 2-d dimen­
sion— 12,65±0,24 cm, 3-d dimension-— 11,41±0,24 cm (p<0,001 if compared to 
NAHS-1 group).
Increase in dimensions of the liver in case of NAFLD and obesity is caused by fat 
and protein dystrophy, inflammatory swelling of hepatocytes, parenchymal infiltration 
and development of the liver fibrosis. Objective increase in dimensions of the liver 
was registered in every second patient in all the observation sub-groups NAHS-1 and 
NASH-2.
All the data provided above highlight the exacerbation of the pathological process 
in the liver and biliary tract in patients suffering from NAFLD and obesity in various 
clinical observation groups.
The comparative analysis of subjective and objective syndromes, inherent to FLD 
of non-alcoholic and alcoholic etiology, demonstrates (Table 1, Figure 1), that in case 
of AHS-3 manifestations of asthenic (in 78% of cases) and dyspeptic (in 94% of cases) 
syndromes are registered more frequent than in patients of NAHS-1 group (respective­
ly in 48%, p<0,001 and 77% of cases, p<0,01). Similar results were obtained from pa­
tients suffering from ASH-4 and NASH-2, in which dyspeptic syndrome was regis­
tered in 94% and 80% of cases, respectively (p<0,05).
According to the frequency of the asthenic syndrome ASH-4 and NASH-2 groups 
were statistically comparable (64% and 63% of patients, respectively provided 
p>0,05), however the degree of severity of the mentioned syndrome was significantly 
higher in patients suffering from NASH — 1,66±0,14 versus 1,48±0,17 (p<0,05).
Prevalence of certain clinical syndromes in patients diagnosed with steatosis and 
steatohepatitis of alcoholic etiology in comparison with groups of patients diagnosed 
with steatosis and steatohepatitis of non-alcoholic etiology has significantly increased. 
To be more specific, the highest degree of severity of the dyspeptic syndrome was re­
vealed in patients of ASH-4 group and on average amounted to 2,14±0,10 versus 
1,82±0,11 in patients from NASH-2 group (p<0,05) and 1,56±0,10 in case of AHS-3 
(p<0,05).
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Table 3
The average degree of severity of the pain syndrome in patients suffering from non-alcoholic and alcoholic fatty liver
disease and obesity, M±m (Me)
L o ca liz a tio n  o f  p a in  and  fac to rs  a sso c ia ted  
w ith  it
N A H S -1 , n = l0 0 N A S H -2 , n=  100 A H S -3 , n= 50 A S H -4 , n= 50
Pain in the right hypochondrium
on  an  e m p ty  sto m ach 0 ,0 4 ± 0 ,0 3  ( 0 ) 3 0 ,1 9 ± 0 ,0 7  (0) 0 ,2 2 ± 0 ,1 0  (0) 0 ,0 6 ± 0 ,0 4  (0)
a fte r m ea ls 1 ,0 9 ± 0 ,1 1(1)* 1 ,45± 0 ,14  (2 ) ' 1 ,18 ± 0 ,14 ( 1 )4 1 ,8 6 ± 0 ,1 5 (2 )J
a fte r physica l loads 0 ,0 8 ± 0 ,0 4  (0) 0 ,0 6 ± 0 ,0 4  (0) 0 ,1 8 ± 0 ,08  (0) 0 ,1 4 ± 0 ,0 8  (0)
d u e  to no  re aso n s 0 ,4 0 ± 0 ,0 9  (0 ) 0 ,2 4 ± 0 ,0 8  (0) 0 ,2 6 ± 0 ,11 (0) 0 ,1 8 ± 0 ,1 0 (0 )
Pain in the left hypochondrium
on an e m p ty  sto m ach 0 ,0 2 ± 0 ,0 2  (0) 0 0 , 14±0,08 (0) 0
a fte r m ea ls 0 ,5 1 ± 0 ,0 9  (O)3 0 ,9 2 ± 0 ,1 3  (0 ) ' 0 ,7 4 ± 0 ,1 4  (0) 1 ,04±0,19 (0)
a fte r  p h y sica l loads ~ ~ <? 0 ,0 3 ± 0 ,0 3  (0) 0 ,1 2 ± 0 ,0 7  (0 ) 1 0
d u e  to no reaso n s 0 ,0 9 ± 0 ,0 4  (0) 0 ,0 3 ± 0 ,0 3  (0) 0 ,2 0 ± 0 ,0 8  (0) 0 ,1 8 ± 0 ,1 0  (0)
Pain in the epigastrium
on an e m p ty  sto m ach 0 ,1 0 ± 0 ,0 4  (0) 0 ,0 2 ± 0 ,0 2  (0) 0 ,1 6 ± 0 ,0 8  (0) 0 ,1 0 ± 0 ,0 7  (0)
a fte r  m eals 0 ,6 2 ± 0 ,10 (0) 0 ,7 5 ± 0 ,12 (0) 0 ,9 0 ± 0 ,1 5  (1) 1,0 ± 0 ,1 7 (0)
a fte r  p h y sica l loads Ô1 0 ,0 3 ± 0 ,0 3  (0) 0 ,1 0 ± 0 ,0 7  (0 ) ' 0 , 14±0,08 (0)
d u e  to no  reaso n s 0 ,0 7 ± 0 ,0 4  (0) 0 ,0 4 ± 0 ,0 3  (0) 0 ,1 8 ± 0 ,0 8  (0) 0 ,1 8 ± 0 ,1 0  (0)
Notes. I'23'4 _  p<0,05 if compared to an appropriate group.
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Table 4
The average degree of severity of disease objective manifestations in patients suffering 
from non-alcoholic and alcoholic fatty liver disease and obesity,
M±m (Me)
F in d in g s  o f  p h y s ic a l  
e x a m in a t io n
N A H S - 1 ,  n = 1 0 0 N A S H - 2 ,  n = l  0 0 A H S - 3 ,  n = 5 0 A S H - 4 ,  n = 5 0
T e n d e r n e s s  o n  p a l p a ­
t i o n  in  th e  r i g h t  h y p o ­
c h o n d r i u m
1 ,7 1 ± 0 ,0 9  ( 2 ) 2 2 ,1 6 ± 0 ,1 2  ( 3 ) 1 1 ,7 4 ± 0 ,1 2  ( 2 ) 4 2 ,4 0 ± 0 ,0 7  ( 2 ) 3
T e n d e r n e s s  o n  p a l p a ­
t i o n  in  t h e  le f t  h y p o ­
c h o n d r i u m
0 ,6 1  ± 0 ,0 9  ( 0 ) 2J 1 , I 0 ± 0 ,1 3  ( 0 ) 1 l , 0 2 ± 0 ,1 4  ( 1 ) 1,4 1 , 4 8 ± 0 , 1 8 ( 2 ) 3
T e n d e r n e s s  o n  p a l p a ­
t i o n  in  th e  e p i g a s t r i u m
0 ,7 7 ± 0 ,0 9  ( 0 ) J 1,0 5 ± 0 , 13 ( 0 ) 4 1 ,3 6 ± 0 ,1 4  ( 1 )  L4 2 ,0 2 ± 0 ,1 4  (2 )
T e n d e r n e s s  o n  p a l p a ­
t i o n  in  th e  i n t e s t i n e
0 ,0 9 ± 0 ,0 5  ( 0 ) 0 ,2 3 ± 0 ,0 8  ( 0 ) 0 , I 4 ± 0 , 0 5  ( 0 ) 0 ,0 8 ± 0 ,0 4  ( 3 )
H e p a t o m e g a l i a 0 ,4 9 ± 0 ,0 5  ( 0 ) 0 ,5 1  ± 0 ,0 5  ( l ) 4 0 ,5 2 ± 0 ,0 7  ( 1 ) 0 ,6 8 ± 0 ,0 7  ( 1 ) J
Notes. L2J'4 _  p<0,05 i f  compared to an appropriate group.
Intensity of the abdominal pain syndrome was the highest in patients from 
NASH-2 group— 2,57±0,08 (Table 2), and patients of ASH-4 group— 2,42±0,07 
(p<0,05 between the groups). The revealed considerable degree of severity of the pain 
syndrome in patients from NASH-2 group may be explained by presence of moderate 
activity of the inflammatory process in 30% of the patients diagnosed with NASH-2, 
while in patients diagnosed with ASH-4 a moderate activity was shown only by 2% of 
the patients. At the very same time, severity of pain in the right and left hypochondri- 
um after meals was the highest in patients suffering from ASH-4 and amounted to 
1,86±0,15 in the right and 1,04±0,19 in the left hypochondrium (Table 4).
The physical examination showed that tenderness on palpation in the right hypo­
chondrium was registered in 100% of patients diagnosed with ASH-4 versus 81% of 
the patients diagnosed with NASH-2 (p<0,01). Tenderness in the left hypochondrium 
was also more pronounced in patients suffering from AHS-3 and ASH-4 and was regis­
tered during the physical examination of 58% and 60% of the patients respectively 
versus 34% and 43% of those from NAHS-1 (p<0,01) and NASH-2 (p<0,05) groups. A 
palpatory pain in the epigastrium was also more frequently registered in patients with 
AHS-3 (78%) and ASH-4 (84%) rather than in patients diagnosed with NAHS-3 
(47%, p<0,001) and NASH-4 (43%, p<0,001). The physical examination showed ap­
proximately equal frequency— 54% of patients diagnosed with AHS-3, 68% of pa­
tients diagnosed with ASH-4, 51% of patients diagnosed with NAHS-1 and 67% 
NASH-2 had hepatomegalia. Dimensions of the liver determined by percussion ac­
cording to Kurloffs approach in patients with AHS-3 were higher than standard rates 
in apparently healthy subjects and in some cases differed from values of the patients of 
NAHS-1 group: 1-st dimension— 12,02±0,27 cm in AHS-3 group and 12,41±0,20 cm 
in NAHS-1 group (p>0,05), 2-d dimension— 10,30±0,19 cm and 11,25±0,19 cm
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(p<0,01), 3-d dimension — 9,02±0,15 cm and 10,13±0,17 cm (p<0,001). In patients 
diagnosed with ASH-4 the degree of hepatomegalia was more pronounced if to com­
pare to indicators of apparently healthy subjects. If compared to NASH-2 group the 
following data was obtained: 1-st dimension— 15,26±0,29 cm in ASH-4 group and 
13,86±0,24 cm in NASH-2 group (p<0,001), 2-d dimension— 12,98±0,24 cm and 
12,65±0,24 cm (p>0,05), 3-d dimension— 10,97±0,16 cm and 11,41±0,24 cm 
(p>0,05).
Among biochemical syndromes accompanying FLD of non-alcoholic and alcohol­
ic genesis there were cytolysis, hepatic secretory obstruction, mesenchymal inflamma­
tion, distortion of protein synthesis function of the liver (Table 5). Most frequently 
NASH-2 group patients revealed increased activity of almost all parameters of cytoly­
sis, hepatic secretory obstructiony, mesenchymal inflammation and indicators of dis­
tortion of protein synthesis function of the liver if to compare to of the patients of 
NAHS-1 group (p<0,05). Presence of cytolysis syndrome was typical for 100% of the 
patients diagnosed with NASH-2 and ASHA. Most frequently NASH-2 and ASHA 
patients revealed increased activity of serum glutamic pyruvic transaminase (ALAT), 
which 4,2 and 3,4 times respectively was higher than values demonstrated by apparent­
ly healthy subjects (p<0,05) and serum glutamic oxaloacetic transaminase (ASAT) 
(3,9 times exceedance, p<0,05) in blood serum. More pronounced increase in level of 
serum glutamic pyruvic transaminase (ALAT) in case of NASH may be explained by 
presence in this group of the patients revealing minimum and moderate activity of dis­
ease; in case of ASH in 98% of cases the patients showing minimum activity of the 
pathological processes prevailed.
Indicators of total bilirubin in all the patients with FLD and obesity were within 
the physiological reference range and did not differ from values in apparently healthy 
subjects. It can only be indicated that total bilirubin was significantly higher in patients 
suffering from NASH-2 and ASHA if compared to patients of NAHS-1 and AHS-3 
group (p<0,05).
Changes in the abovementioned values indicate the formation of cytolytic syn­
drome of minimum or moderate activity in 100% of patients diagnosed with NASH 
and ASH, which was caused by violation of the structural integrity of hepatocytes 
among the examined patients. Activity of alkaline phosphatase was increased in pa­
tients suffering from NAHS-1 and NASH-2 if compared to apparently healthy subjects 
group— 1,6 (p<0,05) and 2,1 times (p<0,05), respectively. In case of AHS-3 and 
ASHA exceedance of alkaline phosphatase level corresponded to 1,8 and 2,0 times 
increase (p<0,05).
Contents of biliary acids in blood exceeded standard ratesl,6 (p<0,05) and b  1,8 
times in case NAHS-1 and NASH-2 (p<0,05). In patients suffering from AHS-3 and 
ASHA the contents of biliary acids also 1,7 (p<0,05) and 2,0 (p<0,05) times respec­
tively exceeded standard rates in apparently healthy subjects.
This being the case, 24% of patients diagnosed with NAHS-1 and 45% of patients 
diagnosed with NASH-2 revealed cholestatic syndrome (p<0,01). In case of AHS-3 
and ASHA the phenomena of hepatic secretory obstruction was observed more fre­
quently if to compare to values of the patients from NAHS-1 and NASH-2 groups and
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amounted to 52% and 58% respectively (pi.3<0,001). The mechanism of cholestatic 
syndrome development among the examined patients diagnosed with NAFLD and 
AFLD against the background of biliary tract pathology and obesity consists in reduc­
tion in the bile flow into the duodenum due to distortion of bile’s synthesis, excretion 
and clearance and as a result violation of biochemical processes in hepatocytes, mani­
fested as disorder of the processes responsible for capturing and output of bile compo­
nents.
As may be seen from the Table 5, significant reduction of albumins contents in 
blood was revealed among patients suffering from NAFLD if compared to standard 
rates— by 10,2% in case of NAHS-1 (p<0,05) and by 15,8% in case of NASH-2 
(p<0,05). If to compare the mentioned groups the differences in values have also been 
statistically significant (p<0,05). Among patients diagnosed with AHS-3 there were 
similar results regarding reduction in albumins by 11,0% (p<0,05) if to compare to ap­
parently healthy subjects. The most reduced level of albumins in blood serum was de­
tected in patients diagnosed with ASH-4 — by 19,3% if compared to apparently 
healthy subjects (p<0,05) and by 9,3% if to compare to AHS-3 group (p<0,05). Reduc­
tion in albumin level, being the dominant representative of the protein fraction, witness 
the distortion of protein synthesis function of the liver among the examined patients 
accompanied by chronization of the pathological process.
The presence of mesenchymal inflammatory syndrome in case of NASH was indi­
cated by hyper-y- globulinemia (within the range of 18,1-25,1% (p<0,05), and 
17,3- 28,6% in case of ASH (p<0,05), which was diagnosed in majority of cases; in­
crease in thymol test values (2,2 times (p<0,05) — in patients diagnosed with 
NASH-2, and 2,6 times (p<0,05) provided the diagnosis of ASH-4, as well as reduction 
in albumin-globulin coefficient (p<0,05).
The presence of mesenchymal inflammatory syndrome in case of NAFLD and 
AFLD and obesity witness the activation of reticuloendothelial system cells and high­
light the activity of the pathological processes.
Obesity of I-III grade, being one of the most spread FLD risk factors (Table 1), 
was most frequently observed among patients diagnosed with NAHS-1 (69%) and pa­
tients with ASH-4 (66%). Values in these groups exceeded the ranges demonstrated by 
patients with AHS-3 (44%) with pi.3<0,01, p3_4<0,05. This being the case, 38% were 
diagnosed with obesity of I grade, 17%— II grade and 14%— III grade among pa­
tients suffering from NAFLD. Among patients diagnosed with AFLD the I grade 
obesity was prevailing; it was diagnosed in 30% of patients, II in 12% and III grade 
only in 2% of the patients. The obtained data are consistent with the research findings, 
which convincingly show, that HBS plays an important role in the regulation of body 
weight, and obesity causes major disturbance in the functioning of the liver and inevi­
tably leads to the development of FLD [2, 13].
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Table 5
Indicators of biochemical blood test in patients diagnosed with fatty liver disease and obesity, M±m
Indicators
Apparently healthy 
subjects, n=20
NAHS-1, n=100 NASH-2, n=100 AHS-3, n=50 ASH-4, n=50
Total bilirubin, mcmole/1 12,11 ±0,74 12,74±0,542 15,66±1,05' 12,20±0,714 16,93±1,784
ALAT, m illimole/hour x 1 0,37±0,02 0,49±0,05J 1,57±0,13"1,4 0,47±0,024 l,24±0,07’ iJ
ASAT, m illimole/hour x 1 0,17±0,02 0,21±0,02] 0 ,6 6 ± 0 ,0 4 '1 0,23±0,024 0,67±0,04"3
Alkaline phosphatase, millim ole/hour x 1 0,68±0,02 1,07±0,06* ‘ 1,43±0,12*1 1,22±0,07* 1,33±0,09*
Biliary acids, millimole/1 0,18±0,01 0,28±0,01 2 0,32±0,01*1 0,33±0,01*1 o ,3 6 ± o ,o r2J
Thymol test, conventional units 2,69±0,22 4,05±0,16*y 5,90±0,19"1,4 5,78±0,28*i;4 7 ,07±0 ,24 'y
Total protein, g/1 79,5±1,0 70,2±0,7‘ 4 67,8±0,8 ' ‘'4 68 ,6 ± 0 ,7 '4 65 ,4 ± 0 ,8 'JJ
Albumins, % 58,1±0,7 52,2±0,6*S 48,9±0,6*1 51,7±0,7*4 46,9± 1 ,0 '5
Globulins, % 37,4±0,5 45,3±0,4*y 48,4±0,6" ''4 49,4±1,0*1,4 54,2±1,4* -’3
a ,, % 4,39±0,12 5,42±0,09*2,3 6 ,44± 0 ,18 '' 6,01 ±0,24*14 7 ,09±0 ,39 'J
a->, % 7,01 ±0,10 8 ,26±0 ,12 'iJ 9 ,65±0,19"1,4 9,27±0,20*14 10,71 ± 0 ,3 2 'y
ß ,% 10,28±0,14
£o
'-H 12,69±0,17*14 12 ,57±0 ,27 'M 14,01±0,43 'i3
Y, % 15,63±0,23 20 ,08±0,15 '-’J 20,92±0,22*1,4 21,55±0,49*1 22,38±0,42*3
Notes. * p<0,05 if  compared to control group; _  p<0,05 if  compared to an appropriate group.
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Conclusions. This being the case, the clinical features of the chronic comorbid 
HBS pathology of non-alcoholic and alcoholic genesis were established; it was also 
found out that FLD is very often accompanied by biliary tract pathology and obesity. 
Clinical features of NAFLD with accompanying biliary tract pathology and obesity 
include intensity of clinical manifestation and a disease course with a predominance of 
asthenic, dyspeptic, abdominal pain syndromes, cholestatic syndrome, hepatomegalia, 
obesity against the background of minimum and moderate manifestations of cytolysis 
and mesenchymal inflammation.
Prospects for further research. Further research must be directed at improving 
of NAFLD and AFLD diagnostic criteria in patients suffering from biliary tract pathol­
ogy and obesity on grounds of parameters of lipid peroxidation, antioxidant defense 
system, endogenous intoxication and markers of the liver fibrosis.
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